Fundraising Fox
/Companies
Sign in

Epicrispr Biotechnologies

South San Francisco, US · Founded 2018 · 51 employees on LinkedIn · 6 known investors

Find your way into Epicrispr Biotechnologies

99 people in our graph share verified history with the Epicrispr Biotechnologies team — schools, employers, funds. One of them is your warm intro.

Noubar Afeyanunlockedknows Amber Salzman · together at Ohana Biosciences, Inc. (overlapped)
knows the team · via Ohana Biosciences, Inc.
×10knows the team · via Bryn Mawr College

Epic CRISPR develops GEMS (Gene Expression Modulation System), a modular epigenetic editing platform that combines DNA-binding proteins, guide RNAs, and modulator proteins to create genetic medicines. The company serves the biotech/medtech sector with advanced tools for precise gene expression control and disease treatment.

AI & Machine LearningBiotechDeep TechHealthtechMedical Devices

Founders & leadership

Epicrispr Biotechnologies was founded in 2018 by Lei Stanley Qi.

LS
Lei Stanley QiScientific Founder
ASAmber Salzman
Amber SalzmanCEOAmber Salzman is CEO of Epicrispr Biotechnologies and previously served as CEO of Ohana Biosciences and Adverum Biotechnologies, a NASDAQ-listed gene therapy company. She spent 25 years at GlaxoSmithKline in R&D leadership overseeing drug development and clinical trials, and earlier founded and sold Cardiokine, a cardiovascular pharmaceutical company. She holds a PhD in Mathematics from Bryn Mawr College and a Bachelor's degree from Temple University.
HZ
Haorui ZhangExecutive

Board

AL
Andrew LamBoard directorManaging Director, Head of Biotech Private Equity at Ally Bridge Group
AL
Anran LiBoard director
JK
Jennifer KingBoard director
EC
Eric CrombezBoard director

Investors · 6

abrdn plcreportedEdinburgh

How we know: funding news · Not right? Tell us

Angelini VenturesreportedRome

How we know: funding news · Not right? Tell us

Fidelity InvestmentsreportedBoston

How we know: funding news · Not right? Tell us

Janus Henderson InvestorsreportedNew York

How we know: press coverage · funding news · Not right? Tell us

Sanofi VenturesreportedCambridge · $5M

How we know: press coverage · funding news · Not right? Tell us

Funding

SEC filings, press & company announcements

$266.8M disclosed across 2 rounds · 2018–2026

▶$176.8MraisedAug 2026 · 47 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Amber SalzmanExecutive Officer, Director
  • Haorui ZhangExecutive Officer, Director
  • Lei QiDirector
  • Andrew LamDirector
  • Jennifer KingDirector
  • Eric CrombezDirector
  • Anran LiDirector
Offering amount
$212.8M
Amount sold
$176.8M
First sale
May 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Epicrispr Biotechnologies Closes $90 Million Oversubscribed Series C Financing to Advance First-in-Class Epigenetic Therapy Toward Pivotal Studies in FSHD - Epicrispr Biotechnologiesepicrispr.com · Aug 2026

Frequently asked questions

What does Epicrispr Biotechnologies do?
Epic CRISPR develops GEMS (Gene Expression Modulation System), a modular epigenetic editing platform that combines DNA-binding proteins, guide RNAs, and modulator proteins to create genetic medicines. The company serves the biotech/medtech sector with advanced tools for precise gene expression control and disease treatment.
Who founded Epicrispr Biotechnologies?
Epicrispr Biotechnologies was founded by Lei Stanley Qi in 2018.
Who are Epicrispr Biotechnologies's investors?
Epicrispr Biotechnologies's investors include Ally Bridge Group, abrdn plc, Angelini Ventures, Fidelity Investments, Janus Henderson Investors, Sanofi Ventures.
How much funding has Epicrispr Biotechnologies raised?
Epicrispr Biotechnologies has disclosed $266.8M raised across 2 rounds.
Where is Epicrispr Biotechnologies headquartered?
Epicrispr Biotechnologies is headquartered in South San Francisco, US.